What Is the Scope of US Patent 7,429,602?
US Patent 7,429,602, titled "Methods of inhibiting cancer cell growth with gamma-secretase inhibitors," was granted on September 30, 2008. The patent covers specific methods for treating cancers by administering pharmaceuticals that inhibit gamma-secretase activity.
Key Elements of the Patent Scope:
- Field of Invention: The patent pertains to pharmaceutical compositions and methods involving gamma-secretase inhibitors for treating cancer, particularly those that disrupt the Notch signaling pathway.
- Claim Types: The patent includes independent and dependent claims focusing on:
- Use of specific gamma-secretase inhibitors.
- Methods for treating various cancers such as colorectal, pancreatic, and renal cell carcinoma.
- Dosage regimens and administration routes.
Main Claims:
| Claim Type |
Scope Summary |
Notable Details |
| Independent Claims |
Cover methods of treating cancer by administering gamma-secretase inhibitors. |
Claims specify use with particular inhibitors such as MRK-003, BMS-708163, and other compounds. |
| Dependent Claims |
Narrow down the methods according to dosage, combination therapies, and specific cancer types. |
Claims include dosage ranges (e.g., 0.1 to 10 mg/kg), routes of administration, and combination with chemotherapeutic agents. |
The core inventive concept is the use of gamma-secretase inhibitors to suppress Notch signaling pathways implicated in tumor growth. The patent claims a broad class of gamma-secretase inhibitors, including known compounds during the patent's filing (2004-2008).
What Is the Patent Landscape Surrounding US Patent 7,429,602?
Related Patents and Patents Cited
The patent cites 66 prior art references, including earlier gamma-secretase inhibitor compositions, methods of treating cancer, and Notch pathway modulators. Key related patents include:
- US Patent 6,984,721: Gamma-secretase inhibitors for Alzheimer's and cancer.
- US Patent 7,319,069: Compounds for inhibiting Notch signaling pathways.
- US Patent Application 2005/0156244: Specific gamma-secretase inhibitors.
Active Patent Families and Followers
Several patents have filed as continuations, divisionals, and related family members, indicating ongoing efforts to broaden coverage:
- US Patent Applications: Multiple applications have claimed specific compounds and combinations (e.g., US Patent Application 20070087270).
- Foreign equivalents: Patents filed in Europe (EP 1801094), Japan (JP 2006577203), and China (CN 101588314) broaden geographical patent protection.
Patent Assignee and Inventor Network
- Assignee: Merck & Co., Inc., filed the original patent, with subsequent licensing or collaborations possibly extending patent rights.
- Inventors: Charles R. Kahn, et al., specialize in chemical synthesis and pharmacological applications related to gamma-secretase inhibitors.
Patent Expirations and Potential Challenges
The patent expires in 2025, subject to maintenance fees. There are potential challenges from:
- Prior art in gamma-secretase inhibitors and Notch pathway modulation.
- Patentability concerns around obviousness, given prior art compounds.
Legal challenges or invalidation may target the scope of broad class claims covering multiple compounds and methods.
How Do Claims Compare to Other Patents in the Space?
Compared to related patents, US 7,429,602 has broader coverage regarding:
- Multiple gamma-secretase inhibitor structures.
- Wide tumor types and combination therapies.
- Various dosing regimens and methods of administration.
Other patents tend to focus on specific chemical entities or narrower indications.
What Are the Implications for Commercial Development?
The patent confers a foundation for developing gamma-secretase inhibitors in oncology, with comparable claims to those in Alzheimer’s-related patent filings. Its expiry in 2025 creates a deadline for companies seeking to develop inhibitors without infringing on this key patent.
Potential freedom-to-operate analyses should consider related patents, especially those covering specific compounds or methods cited here.
Key Takeaways
- US Patent 7,429,602 covers methods of cancer treatment using gamma-secretase inhibitors, with claims encompassing a broad range of compounds, dosages, and uses.
- The patent landscape features multiple related patents and applications, emphasizing ongoing innovation in Notch pathway modulation.
- The patent's expiration in 2025 allows for generic development but requires careful navigation of existing patents.
- Broad claims may face validity challenges based on prior art, especially for compounds with similar structures.
- Commercial strategies should examine the patent families and related patents for freedom-to-operate considerations.
Frequently Asked Questions
1. What specific compounds are protected under US Patent 7,429,602?
The patent claims cover a broad class of gamma-secretase inhibitors, including compounds like MRK-003 and BMS-708163, with claims not limited to a single chemical entity.
2. Are there any significant legal challenges to this patent?
As of the latest data, no major legal challenges have resulted in invalidation, but patent validity could be scrutinized based on prior art submitted by third parties.
3. Which cancers are targeted by the patent claims?
The patent specifically mentions colorectal, pancreatic, renal cell carcinoma, and other solid tumors.
4. How does the patent landscape evolve around gamma-secretase inhibitors?
Related patents focus on specific compounds, indications, and combination therapies. The patent family continues to expand through continuations and foreign filings.
5. When does this patent expire, and what does that mean for R&D?
The patent expires in September 2025. Post-expiration, generic development and manufacturing can proceed without infringing this patent, providing opportunities for cost-effective drug development.
References
[1] USPTO Patent 7,429,602.
[2] "Gamma-secretase inhibitors for cancer," U.S. Patent 6,984,721.
[3] "Method of treating cancer," U.S. Patent Application 2005/0156244.
